Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes
Latest Information Update: 15 Dec 2022
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPA-HEART; EMPA-HEART CardioLink-6 trial
- 07 Nov 2022 Results presented at the American Heart Association Scientific Sessions 2022
- 01 Apr 2022 Results assessing whether baseline LVMi influences empagliflozin-associated cardiac reverse remodeling in patients from empagliflozin treatment arm of EMPA-HEART CardioLink-6 trial , published in the Acta Diabetologica
- 11 Mar 2020 Results of a sub-analysis from this trial published in the Nephrology Dialysis Transplantation.